Information Provided By: 
Fly News Breaks for October 23, 2015
ZSPH
Oct 23, 2015 | 07:13 EDT
Morgan Stanley upgraded ZS Pharma to Overweight and increased its price target on shares to $76 from $67. Analyst Andrew Berens said the restrictive label for competitor Relypsa's (RLYP) Veltassa is a significant handicap for the drug and a best case for ZS Pharm's ZS-9. Berens sees less regulatory risk for ZS-9 and expects it to emerge as a best-in-class drug.
News For ZSPH From the Last 2 Days
There are no results for your query ZSPH
